• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT GMBH LACTATE DEHYDROGENASE (LDH); NAD REDUCTION/NADH OXIDATION, LACTATE DEHYDROGENASE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT GMBH LACTATE DEHYDROGENASE (LDH); NAD REDUCTION/NADH OXIDATION, LACTATE DEHYDROGENASE Back to Search Results
Model Number 2P56-22
Device Problem High Test Results (2457)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 12/09/2020
Event Type  malfunction  
Manufacturer Narrative
Complete information for section a patient information, 1.Patient identifier = sid= (b)(4) an evaluation is in process.A follow-up report will be submitted when the evaluation is complete.
 
Event Description
The customer observed falsely elevated lactate dehydrogenase (ldh) results on architect c16000 processing module for one patient.The results provided were: on (b)(6) 2020 sid (b)(6) initial ldh= 371 u/l /repeated=582 u/l /repeated=366 u/l and 380 u/l.There was no reported impact to patient management.
 
Manufacturer Narrative
A review of complaints found no trends for the complaint issue.Return testing was not completed as returns were not available.No file sample testing performed as the issue is sample / tube specific at the customer site; the customer generated acceptable results using the same reagent.Device history record review did not identify any non-conformances or deviations with the likely cause lot and complaint issue.A review of the manufacturing documentation did not identify any issues associated with the customer's observation.Labeling was reviewed and multiple probable causes were identified: handle specimen collection and sample tube processing per the tube manufacturer's instructions.So handled, plasma may still contain cellular elements which can interfere with the ldh measurements due to presence of the enzyme in the cells or cellular debris or sample handling issues.Based on the investigation no product deficiency was identified for the lactate dehydrogenase (ldh) assay reagent, lot 02747un20.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
LACTATE DEHYDROGENASE (LDH)
Type of Device
NAD REDUCTION/NADH OXIDATION, LACTATE DEHYDROGENASE
Manufacturer (Section D)
ABBOTT GMBH
max-planck-ring 2
wiesbaden 65205
GM  65205
MDR Report Key11080353
MDR Text Key241307352
Report Number3002809144-2020-01206
Device Sequence Number1
Product Code CFJ
UDI-Device Identifier00380740161460
UDI-Public00380740161460
Combination Product (y/n)N
PMA/PMN Number
EXEMPT
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup
Report Date 01/15/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date06/16/2021
Device Model Number2P56-22
Device Catalogue Number02P56-22
Device Lot Number02747UN20
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 12/09/2020
Initial Date FDA Received12/28/2020
Supplement Dates Manufacturer Received01/14/2021
Supplement Dates FDA Received01/15/2021
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ARC C16K PRC MOD, 03L77-01, C1600596; ARC C16K PRC MOD, 03L77-01, C1600596
-
-